With $290M in hand, newly emerged biotech Metsera thinks customizable combos are the future of obesity treatments
Fierce Biotech -

Clinical-stage Metsera has emerged from stealth with $290 million in hand and the bold vision of ushering in the next generation of obesity and metabolic disease medicines. | Clinical-stage Metsera has emerged from stealth with $290 million in hand and the bold vision of ushering in the next generation of obesity and metabolic disease medicines.

In related news